Review




Structured Review

Proteintech mn1
Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and <t>MN1.</t> The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Mn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mn1/product/Proteintech
Average 93 stars, based on 5 article reviews
mn1 - by Bioz Stars, 2026-03
93/100 stars

Images

1) Product Images from "Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis"

Article Title: Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1580986

Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and MN1. The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure Legend Snippet: Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and MN1. The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Techniques Used: Expressing



Similar Products

96
ATCC rhamnolipid surfactin p aeruginosa mn1 bacillus amyloliquefaciens ns6 s mutans atcc 35668 antibiofilm activity lowers surface tension
Rhamnolipid Surfactin P Aeruginosa Mn1 Bacillus Amyloliquefaciens Ns6 S Mutans Atcc 35668 Antibiofilm Activity Lowers Surface Tension, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhamnolipid surfactin p aeruginosa mn1 bacillus amyloliquefaciens ns6 s mutans atcc 35668 antibiofilm activity lowers surface tension/product/ATCC
Average 96 stars, based on 1 article reviews
rhamnolipid surfactin p aeruginosa mn1 bacillus amyloliquefaciens ns6 s mutans atcc 35668 antibiofilm activity lowers surface tension - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
iQ Biosciences cynomolgus monkey cd14 cells
BAL-0028 inhibits primate NLRP3 but is a poor inhibitor of NLRP3 from other mammals. Comparison of BAL-0028 and MCC950 in IL-1β release assays from cells stimulated with LPS and nigericin. (A–I) J774A.1 mouse macrophage cell line (A), Wistar rat PBMCs (B), Beagle <t>CD14</t> + monocytes (C), New Zealand white rabbit PBMCs (D), African green monkey ( C. sabaeus ) PBMCs (E) and CD14 + monocytes (F), <t>cynomolgus</t> monkey ( M. fascicularis ) CD14 + monocytes (G), WT 129S6 iBMDM (H), and 129S6-human promoter NLRP3 iBMDM (I). (A, H, and I) Graph symbols show average IL-1β values relative to vehicle control ± SEM from N = 3 independent experiments performed in triplicate. (B–G) Graph symbols show average IL-1β values relative to vehicle control ± SD from one experiment performed in duplicate (C, D, and F) or triplicate (B, E, and G). IC 50 curves were fitted by nonlinear regression analysis.
Cynomolgus Monkey Cd14 Cells, supplied by iQ Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cynomolgus monkey cd14 cells/product/iQ Biosciences
Average 94 stars, based on 1 article reviews
cynomolgus monkey cd14 cells - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Proteintech mn1
Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and <t>MN1.</t> The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Mn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mn1/product/Proteintech
Average 93 stars, based on 1 article reviews
mn1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech anti mn1
Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and <t>MN1.</t> The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Anti Mn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mn1/product/Proteintech
Average 93 stars, based on 1 article reviews
anti mn1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech anti mn1 antibody
XIST regulates <t>MN1</t> expression through miR-15a-5p. (A) Volcano plot illustrating the differentially expressed genes between XIST-shRNA and control groups in T24 cells. (B, C) KEGG pathway analysis of (B) upregulated and (C) downregulated genes following XIST knockdown. (D) Venn diagram showing the overlap between XIST ceRNA target genes and downregulated genes after XIST knockdown. (E) Expression levels of MN1, SH3PXD2A, and TFP1 genes in male and female bladder cancer patients. (F) Prognostic significance of MN1, SH3PXD2A, and TFP1 gene expression in bladder cancer patients. (G) Prognostic impact of MN1 expression in male and female bladder cancer patients. (H) Effect of XIST overexpression on MN1 mRNA and protein levels in T24 cells. (I) Effect of XIST overexpression on MN1 mRNA and protein levels in RT4 cells. (J) Volcano plot illustrating the differentially expressed miRNAs between XIST-shRNA and control groups in T24 cells. (K) Correlation analysis between MN1 and miR-15a expression. (L) Effect of XIST knockdown on miR-15a-5p expression in T24 and RT4 cells. (M, N) Effect of miR-15a-5p overexpression on MN1 mRNA and protein levels in (M) T24 and (N) RT4 cells. (O) Dual-luciferase reporter assay demonstrating the interaction between XIST and miR-15a-5p. (P, Q) Effect of miR-15a-5p on XIST expression in (P) T24 and (Q) RT4 cells. (R) Dual-luciferase reporter assay demonstrating the interaction between MN1 and miR-15a-5p. (S, T) Effect of miR-15a-5p on MN1 expression in (S) T24 and (T) RT4 cells. *p<0.05, **p<0.01, ***p<0.001.
Anti Mn1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mn1 antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
anti mn1 antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Biorbyt krt14
The primer sequences for the target genes
Krt14, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/krt14/product/Biorbyt
Average 93 stars, based on 1 article reviews
krt14 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Biotechnology Information mn1 (ty813)
The primer sequences for the target genes
Mn1 (Ty813), supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mn1 (ty813)/product/Biotechnology Information
Average 90 stars, based on 1 article reviews
mn1 (ty813) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

96
ATCC characteristic m novusgordonae mn1 m shingordonae ms1 m paragordonae
The primer sequences for the target genes
Characteristic M Novusgordonae Mn1 M Shingordonae Ms1 M Paragordonae, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/characteristic m novusgordonae mn1 m shingordonae ms1 m paragordonae/product/ATCC
Average 96 stars, based on 1 article reviews
characteristic m novusgordonae mn1 m shingordonae ms1 m paragordonae - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

85
Thermo Fisher gene exp mn1 hs00159202 m1
The primer sequences for the target genes
Gene Exp Mn1 Hs00159202 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp mn1 hs00159202 m1/product/Thermo Fisher
Average 85 stars, based on 1 article reviews
gene exp mn1 hs00159202 m1 - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier

Image Search Results


BAL-0028 inhibits primate NLRP3 but is a poor inhibitor of NLRP3 from other mammals. Comparison of BAL-0028 and MCC950 in IL-1β release assays from cells stimulated with LPS and nigericin. (A–I) J774A.1 mouse macrophage cell line (A), Wistar rat PBMCs (B), Beagle CD14 + monocytes (C), New Zealand white rabbit PBMCs (D), African green monkey ( C. sabaeus ) PBMCs (E) and CD14 + monocytes (F), cynomolgus monkey ( M. fascicularis ) CD14 + monocytes (G), WT 129S6 iBMDM (H), and 129S6-human promoter NLRP3 iBMDM (I). (A, H, and I) Graph symbols show average IL-1β values relative to vehicle control ± SEM from N = 3 independent experiments performed in triplicate. (B–G) Graph symbols show average IL-1β values relative to vehicle control ± SD from one experiment performed in duplicate (C, D, and F) or triplicate (B, E, and G). IC 50 curves were fitted by nonlinear regression analysis.

Journal: The Journal of Experimental Medicine

Article Title: Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action

doi: 10.1084/jem.20242403

Figure Lengend Snippet: BAL-0028 inhibits primate NLRP3 but is a poor inhibitor of NLRP3 from other mammals. Comparison of BAL-0028 and MCC950 in IL-1β release assays from cells stimulated with LPS and nigericin. (A–I) J774A.1 mouse macrophage cell line (A), Wistar rat PBMCs (B), Beagle CD14 + monocytes (C), New Zealand white rabbit PBMCs (D), African green monkey ( C. sabaeus ) PBMCs (E) and CD14 + monocytes (F), cynomolgus monkey ( M. fascicularis ) CD14 + monocytes (G), WT 129S6 iBMDM (H), and 129S6-human promoter NLRP3 iBMDM (I). (A, H, and I) Graph symbols show average IL-1β values relative to vehicle control ± SEM from N = 3 independent experiments performed in triplicate. (B–G) Graph symbols show average IL-1β values relative to vehicle control ± SD from one experiment performed in duplicate (C, D, and F) or triplicate (B, E, and G). IC 50 curves were fitted by nonlinear regression analysis.

Article Snippet: Cryopreserved Beagle canine CD14 + , cynomolgus monkey CD14 + cells, New Zealand white rabbit PBMCs, and Wistar rat PBMCs were obtained from IQ Biosciences.

Techniques: Comparison, Control

BAL-0598 inhibits the activation of human and monkey NLRP3 and is a non-covalent inhibitor . Related to and . (A) BAL-0598 in IL-1β release assay from PMA-differentiated THP-1 cells stimulated with LPS and MSU. (B) BAL-0598 effect on ASC speck formation assessed by fluorescence microscopy in PMA-differentiated THP-1 ASC-GFP cells stimulated with LPS and nigericin. (C and D) Comparison of BAL-0598, BAL-0028, and MCC950 in an LDH release assay in primary peritoneal macrophages isolated from (C) WT 129S6 or (D) 129S6 mouse promoter- NLRP3 mice stimulated with LPS and ATP. Graph symbols show average LDH values ± SEM from N = 2 independent experiments performed in duplicate. (E and F) BAL-0598 in IL-1β release assays from cells stimulated with LPS and nigericin. African green monkey CD14 + monocytes (E) and PBMCs (F). (A, B, E, and F) Graph symbols show average values relative to vehicle control ± SEM (A, N = 2) or SD (B, E, and F, N = 1) from independent experiments performed in duplicate (E) or triplicate (A, B, and F); IC 50 curve was fitted by nonlinear regression analysis. (G) Comparison of BAL-0028, BAL-0598, and MCC950 in an IL-1β release assay from PMA-differentiated THP-1 cells stimulated with LPS and nigericin. Cells were treated with compounds before nigericin stimulation, and compounds were left on or were washed out for 1 min before nigericin addition. The graph shows average IL-1β values ± SD from one experiment performed in triplicate. (H) Schematic illustration of U937 NLRP3 and NLRP3-AID mutant cell model.

Journal: The Journal of Experimental Medicine

Article Title: Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action

doi: 10.1084/jem.20242403

Figure Lengend Snippet: BAL-0598 inhibits the activation of human and monkey NLRP3 and is a non-covalent inhibitor . Related to and . (A) BAL-0598 in IL-1β release assay from PMA-differentiated THP-1 cells stimulated with LPS and MSU. (B) BAL-0598 effect on ASC speck formation assessed by fluorescence microscopy in PMA-differentiated THP-1 ASC-GFP cells stimulated with LPS and nigericin. (C and D) Comparison of BAL-0598, BAL-0028, and MCC950 in an LDH release assay in primary peritoneal macrophages isolated from (C) WT 129S6 or (D) 129S6 mouse promoter- NLRP3 mice stimulated with LPS and ATP. Graph symbols show average LDH values ± SEM from N = 2 independent experiments performed in duplicate. (E and F) BAL-0598 in IL-1β release assays from cells stimulated with LPS and nigericin. African green monkey CD14 + monocytes (E) and PBMCs (F). (A, B, E, and F) Graph symbols show average values relative to vehicle control ± SEM (A, N = 2) or SD (B, E, and F, N = 1) from independent experiments performed in duplicate (E) or triplicate (A, B, and F); IC 50 curve was fitted by nonlinear regression analysis. (G) Comparison of BAL-0028, BAL-0598, and MCC950 in an IL-1β release assay from PMA-differentiated THP-1 cells stimulated with LPS and nigericin. Cells were treated with compounds before nigericin stimulation, and compounds were left on or were washed out for 1 min before nigericin addition. The graph shows average IL-1β values ± SD from one experiment performed in triplicate. (H) Schematic illustration of U937 NLRP3 and NLRP3-AID mutant cell model.

Article Snippet: Cryopreserved Beagle canine CD14 + , cynomolgus monkey CD14 + cells, New Zealand white rabbit PBMCs, and Wistar rat PBMCs were obtained from IQ Biosciences.

Techniques: Activation Assay, Release Assay, Fluorescence, Microscopy, Comparison, Lactate Dehydrogenase Assay, Isolation, Control, Mutagenesis

Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and MN1. The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Journal: Frontiers in Immunology

Article Title: Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis

doi: 10.3389/fimmu.2025.1580986

Figure Lengend Snippet: Machine learning algorithms to obtain hub targets of C3 subtype. (A) The identification of potential targets using the randomForest and Lasso algorithm in C3 subtype. (B) Survival analysis for AHANK2, SLC9B2, and MN1. The relative expression of different stages and grades for AHANK2, SLC9B2, and MN1, respectively. (C) GSEA enrichment analysis for AHANK2, SLC9B2, and MN1 based on hallmark gene set. (D) Correlation between 22 infiltrating immune cells and AHANK2, SLC9B2, and MN1, respectively. (E) WB and the relative expression of AHANK2, SLC9B2, and MN1 proteins in different tumor stages. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: Among them, primary antibodies included: FAT4 (1:1000; PA5-72970, Invitrogen, China), RPL37P1 (1:1000; ab228542, Abcam, China), FGFR1 (1:1000; R381166, Zenbio, China), RNASEH1 (1:1000; 82771-1-RR, Proteintech, China), AHNAK2 (1:1000; 680021, Zenbio, China), SLC9B2 (1:1000; 24065-1-AP, Proteintech, China), MN1 (1:1000; 24697-1-AP, Proteintech, China), TTLL3 (1:1000; PA5-70598, Invitrogen, China), FABP6 (1:1000; 126828, Zenbio, China), TBC1D3 (1:1000; DF3346, Affinity, China).

Techniques: Expressing

XIST regulates MN1 expression through miR-15a-5p. (A) Volcano plot illustrating the differentially expressed genes between XIST-shRNA and control groups in T24 cells. (B, C) KEGG pathway analysis of (B) upregulated and (C) downregulated genes following XIST knockdown. (D) Venn diagram showing the overlap between XIST ceRNA target genes and downregulated genes after XIST knockdown. (E) Expression levels of MN1, SH3PXD2A, and TFP1 genes in male and female bladder cancer patients. (F) Prognostic significance of MN1, SH3PXD2A, and TFP1 gene expression in bladder cancer patients. (G) Prognostic impact of MN1 expression in male and female bladder cancer patients. (H) Effect of XIST overexpression on MN1 mRNA and protein levels in T24 cells. (I) Effect of XIST overexpression on MN1 mRNA and protein levels in RT4 cells. (J) Volcano plot illustrating the differentially expressed miRNAs between XIST-shRNA and control groups in T24 cells. (K) Correlation analysis between MN1 and miR-15a expression. (L) Effect of XIST knockdown on miR-15a-5p expression in T24 and RT4 cells. (M, N) Effect of miR-15a-5p overexpression on MN1 mRNA and protein levels in (M) T24 and (N) RT4 cells. (O) Dual-luciferase reporter assay demonstrating the interaction between XIST and miR-15a-5p. (P, Q) Effect of miR-15a-5p on XIST expression in (P) T24 and (Q) RT4 cells. (R) Dual-luciferase reporter assay demonstrating the interaction between MN1 and miR-15a-5p. (S, T) Effect of miR-15a-5p on MN1 expression in (S) T24 and (T) RT4 cells. *p<0.05, **p<0.01, ***p<0.001.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: XIST regulates MN1 expression through miR-15a-5p. (A) Volcano plot illustrating the differentially expressed genes between XIST-shRNA and control groups in T24 cells. (B, C) KEGG pathway analysis of (B) upregulated and (C) downregulated genes following XIST knockdown. (D) Venn diagram showing the overlap between XIST ceRNA target genes and downregulated genes after XIST knockdown. (E) Expression levels of MN1, SH3PXD2A, and TFP1 genes in male and female bladder cancer patients. (F) Prognostic significance of MN1, SH3PXD2A, and TFP1 gene expression in bladder cancer patients. (G) Prognostic impact of MN1 expression in male and female bladder cancer patients. (H) Effect of XIST overexpression on MN1 mRNA and protein levels in T24 cells. (I) Effect of XIST overexpression on MN1 mRNA and protein levels in RT4 cells. (J) Volcano plot illustrating the differentially expressed miRNAs between XIST-shRNA and control groups in T24 cells. (K) Correlation analysis between MN1 and miR-15a expression. (L) Effect of XIST knockdown on miR-15a-5p expression in T24 and RT4 cells. (M, N) Effect of miR-15a-5p overexpression on MN1 mRNA and protein levels in (M) T24 and (N) RT4 cells. (O) Dual-luciferase reporter assay demonstrating the interaction between XIST and miR-15a-5p. (P, Q) Effect of miR-15a-5p on XIST expression in (P) T24 and (Q) RT4 cells. (R) Dual-luciferase reporter assay demonstrating the interaction between MN1 and miR-15a-5p. (S, T) Effect of miR-15a-5p on MN1 expression in (S) T24 and (T) RT4 cells. *p<0.05, **p<0.01, ***p<0.001.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques: Expressing, shRNA, Control, Knockdown, Gene Expression, Over Expression, Luciferase, Reporter Assay

The impact of miR-15a-5p and MN1 on the proliferation and metastasis of bladder cancer cells. (A) RT-PCR analysis of miR-15a-5p expression in T24 cells following transfection with miR-15a-5p-mimic. (B–D) Impact of miR-15a-5p transfection on the (B) proliferation, (C) migration, and (D) invasion capabilities of T24 cells. (E) RT-PCR analysis of miR-15a-5p expression in RT4 cells following transfection with miR-15a-5p-mimic. (F–H) Impact of miR-15a-5p transfection on the (F) proliferation, (G) migration, and (H) invasion capabilities of RT4 cells. (I) Western blot analysis of MN1 expression in T24 cells following MN1 overexpression. (J–L) Impact of MN1 overexpression on the (J) proliferation, (K) migration, and (L) invasion capabilities of T24 cells. (M) Western blot analysis of MN1 expression in RT4 cells following MN1 overexpression. (N–P) Impact of MN1 overexpression on the (N) proliferation, (O) migration, and (P) invasion capabilities of RT4 cells. (Q, R) Impact of MN1 overexpression on the (Q) proliferation and (R) metastasis capabilities of T24 cells in the zebrafish model. (S, T) Impact of MN1 overexpression on the (S) proliferation and (T) metastasis capabilities of RT4 cells in the zebrafish model. *p<0.05, **p<0.01, ***p<0.001. ns, p>0.05.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: The impact of miR-15a-5p and MN1 on the proliferation and metastasis of bladder cancer cells. (A) RT-PCR analysis of miR-15a-5p expression in T24 cells following transfection with miR-15a-5p-mimic. (B–D) Impact of miR-15a-5p transfection on the (B) proliferation, (C) migration, and (D) invasion capabilities of T24 cells. (E) RT-PCR analysis of miR-15a-5p expression in RT4 cells following transfection with miR-15a-5p-mimic. (F–H) Impact of miR-15a-5p transfection on the (F) proliferation, (G) migration, and (H) invasion capabilities of RT4 cells. (I) Western blot analysis of MN1 expression in T24 cells following MN1 overexpression. (J–L) Impact of MN1 overexpression on the (J) proliferation, (K) migration, and (L) invasion capabilities of T24 cells. (M) Western blot analysis of MN1 expression in RT4 cells following MN1 overexpression. (N–P) Impact of MN1 overexpression on the (N) proliferation, (O) migration, and (P) invasion capabilities of RT4 cells. (Q, R) Impact of MN1 overexpression on the (Q) proliferation and (R) metastasis capabilities of T24 cells in the zebrafish model. (S, T) Impact of MN1 overexpression on the (S) proliferation and (T) metastasis capabilities of RT4 cells in the zebrafish model. *p<0.05, **p<0.01, ***p<0.001. ns, p>0.05.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Transfection, Migration, Western Blot, Over Expression

The impact of XIST on the proliferation and metastasis of bladder cancer cells is related to MN1. (A) Western blot analysis of MN1 expression in T24 cells after transfection with XIST-shRNA and MN1-OS. (B–D) Impact of XIST-shRNA and MN1-OS transfection on the (B) proliferation, (C) migration, and (D) invasion capabilities of T24 cells. (E) Western blot analysis of MN1 expression in RT4 cells after transfection with XIST-shRNA and MN1-OS. (F–H) Impact of XIST-shRNA and MN1-OS transfection on the (F) proliferation, (G) migration, and (H) invasion capabilities of RT4 cells. *p<0.05, **p<0.01, ***p<0.001. ns, p>0.05.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: The impact of XIST on the proliferation and metastasis of bladder cancer cells is related to MN1. (A) Western blot analysis of MN1 expression in T24 cells after transfection with XIST-shRNA and MN1-OS. (B–D) Impact of XIST-shRNA and MN1-OS transfection on the (B) proliferation, (C) migration, and (D) invasion capabilities of T24 cells. (E) Western blot analysis of MN1 expression in RT4 cells after transfection with XIST-shRNA and MN1-OS. (F–H) Impact of XIST-shRNA and MN1-OS transfection on the (F) proliferation, (G) migration, and (H) invasion capabilities of RT4 cells. *p<0.05, **p<0.01, ***p<0.001. ns, p>0.05.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques: Western Blot, Expressing, Transfection, shRNA, Migration

Expression of XIST/miR-15a-5p/MN1 in bladder cancer. (A, B) XIST expression levels in (A) 50 female and (B) 50 male bladder cancer patient specimens. (C, D) miR-15a-5p expression levels in (C) 50 female and (D) 50 male bladder cancer patient specimens. (E, F) MN1 mRNA expression levels in (E) 50 female and (F) 50 male bladder cancer patient specimens. (G, H) Immunohistochemical analysis of MN1 protein expression in (G) 50 female and (H) 50 male bladder cancer patient specimens. (I) Comparative analysis of MN1 protein expression in male and female bladder cancer patient specimens. *** p< 0.001. **p<0.01.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: Expression of XIST/miR-15a-5p/MN1 in bladder cancer. (A, B) XIST expression levels in (A) 50 female and (B) 50 male bladder cancer patient specimens. (C, D) miR-15a-5p expression levels in (C) 50 female and (D) 50 male bladder cancer patient specimens. (E, F) MN1 mRNA expression levels in (E) 50 female and (F) 50 male bladder cancer patient specimens. (G, H) Immunohistochemical analysis of MN1 protein expression in (G) 50 female and (H) 50 male bladder cancer patient specimens. (I) Comparative analysis of MN1 protein expression in male and female bladder cancer patient specimens. *** p< 0.001. **p<0.01.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques: Expressing, Immunohistochemical staining

XIST/miR-15a-5p/MN1 regulates FZD2 expression. (A) Volcano plot illustrating differentially expressed genes in T24 cells transfected with MN1-shRNA compared to the control group. (B, C) KEGG pathway analysis of (B) upregulated and (C) downregulated genes following MN1 knockdown. (D) Venn diagram depicting the intersection of downregulated genes after XIST and MN1 knockdown. (E) Differentially expressed downregulated intersecting genes in male versus female bladder cancer. (F) Venn diagram showing the intersection of upregulated genes after XIST and MN1 knockdown. (G) Differentially expressed upregulated intersecting genes in male versus female bladder cancer specimens. (H) Prognostic analysis of FZD2 in female bladder cancer. (I, J) Effects of (I) XIST knockdown and (J) MN1 knockdown on FZD2 expression in T24 cells. (K, L) Effects of (K) XIST knockdown and (L) MN1 knockdown on FZD2 expression in RT4 cells. *p<0.05, **p<0.01.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: XIST/miR-15a-5p/MN1 regulates FZD2 expression. (A) Volcano plot illustrating differentially expressed genes in T24 cells transfected with MN1-shRNA compared to the control group. (B, C) KEGG pathway analysis of (B) upregulated and (C) downregulated genes following MN1 knockdown. (D) Venn diagram depicting the intersection of downregulated genes after XIST and MN1 knockdown. (E) Differentially expressed downregulated intersecting genes in male versus female bladder cancer. (F) Venn diagram showing the intersection of upregulated genes after XIST and MN1 knockdown. (G) Differentially expressed upregulated intersecting genes in male versus female bladder cancer specimens. (H) Prognostic analysis of FZD2 in female bladder cancer. (I, J) Effects of (I) XIST knockdown and (J) MN1 knockdown on FZD2 expression in T24 cells. (K, L) Effects of (K) XIST knockdown and (L) MN1 knockdown on FZD2 expression in RT4 cells. *p<0.05, **p<0.01.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques: Expressing, Transfection, shRNA, Control, Knockdown

A mechanistic diagram. In female bladder cancer, the XIST/miR-15a-5p/MN1/FZD2 axis is overactivated, thereby promoting the malignant progression of bladder cancer.

Journal: Frontiers in Immunology

Article Title: The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis

doi: 10.3389/fimmu.2025.1554829

Figure Lengend Snippet: A mechanistic diagram. In female bladder cancer, the XIST/miR-15a-5p/MN1/FZD2 axis is overactivated, thereby promoting the malignant progression of bladder cancer.

Article Snippet: The sections were then incubated overnight at 4°C with an anti-MN1 antibody at a 1:100 dilution (Proteintech, China).

Techniques:

The primer sequences for the target genes

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: The primer sequences for the target genes

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Sequencing

KRT14 expression levels in ovarian cancer cell lines SK-OV-3 and A2780 and their cisplatin-resistant variants SK-OV-3/DDP and A2780/DDP. (A) KRT14 mRNA expression levels detected using qRT-PCR. (B) KRT14 protein expression levels visualized using Western blot analysis. Right bar graph: KRT14 protein levels relative to GAPDH. *, statistical significance (P<0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: KRT14 expression levels in ovarian cancer cell lines SK-OV-3 and A2780 and their cisplatin-resistant variants SK-OV-3/DDP and A2780/DDP. (A) KRT14 mRNA expression levels detected using qRT-PCR. (B) KRT14 protein expression levels visualized using Western blot analysis. Right bar graph: KRT14 protein levels relative to GAPDH. *, statistical significance (P<0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Reverse Transcription, Polymerase Chain Reaction

KRT14 knockdown reduces SK-OV-3/DDP and A2780/DDP cell viability. si-KRT14 was transfected into cells to achieve KRT14 knockdown, with cells transfected with si-NC and un-transfected cells (blank cells) serving as controls. (A) KRT14 mRNA levels. (B) KRT14 protein levels. Right bar graph: KRT14 protein levels relative to GAPDH. (C) Viability of SK-OV-3/DDP and A2780/DDP cells in the three groups after treatment with varying concentrations of cisplatin (0, 2.5, 5, 10, 20, 40, and 80 µM). (D) Fitting curves used to determine the IC 50 values of SK-OV-3/DDP and A2780/DDP cells in response to cisplatin. *, statistical significance (P<0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC 50 , half-maximal inhibitory concentration; KRT14, keratin 14; mRNA, messenger RNA; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: KRT14 knockdown reduces SK-OV-3/DDP and A2780/DDP cell viability. si-KRT14 was transfected into cells to achieve KRT14 knockdown, with cells transfected with si-NC and un-transfected cells (blank cells) serving as controls. (A) KRT14 mRNA levels. (B) KRT14 protein levels. Right bar graph: KRT14 protein levels relative to GAPDH. (C) Viability of SK-OV-3/DDP and A2780/DDP cells in the three groups after treatment with varying concentrations of cisplatin (0, 2.5, 5, 10, 20, 40, and 80 µM). (D) Fitting curves used to determine the IC 50 values of SK-OV-3/DDP and A2780/DDP cells in response to cisplatin. *, statistical significance (P<0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC 50 , half-maximal inhibitory concentration; KRT14, keratin 14; mRNA, messenger RNA; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Knockdown, Transfection, Concentration Assay, Negative Control, Small Interfering RNA

KRT14 knockdown increases apoptosis and decreases MDR-related protein expression in SK-OV-3/DDP and A2780/DDP cells. si-KRT14 was transfected into cells to achieve KRT14 knockdown, with cells transfected with si-NC and untransfected cells (blank cell) serving as controls. (A,B) Apoptotic cell rates assessed using flow cytometry and Hoechst 33258 staining, respectively. The magnification is 20× and the green arrows indicate the apoptotic cells. (C) P-gp and MRP1 protein levels. Right bar graph: P-gp and MRP1 protein levels relative to GAPDH. *, statistical significance (P<0.05). FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; MDR, multidrug resistance; MRP1, multidrug resistance-associated protein 1; P-gp, P-glycoprotein; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: KRT14 knockdown increases apoptosis and decreases MDR-related protein expression in SK-OV-3/DDP and A2780/DDP cells. si-KRT14 was transfected into cells to achieve KRT14 knockdown, with cells transfected with si-NC and untransfected cells (blank cell) serving as controls. (A,B) Apoptotic cell rates assessed using flow cytometry and Hoechst 33258 staining, respectively. The magnification is 20× and the green arrows indicate the apoptotic cells. (C) P-gp and MRP1 protein levels. Right bar graph: P-gp and MRP1 protein levels relative to GAPDH. *, statistical significance (P<0.05). FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; MDR, multidrug resistance; MRP1, multidrug resistance-associated protein 1; P-gp, P-glycoprotein; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Knockdown, Expressing, Transfection, Flow Cytometry, Staining, Negative Control, Small Interfering RNA

Effect of KRT14 knockdown on LRP11 expression. To achieve KRT14 knockdown, cells were transfected with si-KRT14, with cells transfected with si-NC used as a control. (A) Volcano plots of differentially expressed mRNAs identified by Illumina RNA sequencing following KRT14 knockdown. (B) Venn diagram of differentially expressed mRNAs in both SK-OV-3/DDP and A2780/DDP cells. (C) Expression levels of MTAP, LRP11, NUDT16, and RBM15 in KRT14 knockdown cells as measured by qRT-PCR. (D) Western blot results for LRP11 expression in KRT14 knockdown cells. Right bar graph: LRP11 protein levels relative to GAPDH. *, statistical significance (P<0.05). FDR, false discovery rate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; mRNA, messenger RNA; MTAP, methylthioadenosine phosphorylase; NUDT16, nudix hydrolase 16; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; RBM15, RNA binding motif protein 15; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: Effect of KRT14 knockdown on LRP11 expression. To achieve KRT14 knockdown, cells were transfected with si-KRT14, with cells transfected with si-NC used as a control. (A) Volcano plots of differentially expressed mRNAs identified by Illumina RNA sequencing following KRT14 knockdown. (B) Venn diagram of differentially expressed mRNAs in both SK-OV-3/DDP and A2780/DDP cells. (C) Expression levels of MTAP, LRP11, NUDT16, and RBM15 in KRT14 knockdown cells as measured by qRT-PCR. (D) Western blot results for LRP11 expression in KRT14 knockdown cells. Right bar graph: LRP11 protein levels relative to GAPDH. *, statistical significance (P<0.05). FDR, false discovery rate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; mRNA, messenger RNA; MTAP, methylthioadenosine phosphorylase; NUDT16, nudix hydrolase 16; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; RBM15, RNA binding motif protein 15; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Knockdown, Expressing, Transfection, Control, RNA Sequencing, Quantitative RT-PCR, Western Blot, Reverse Transcription, Polymerase Chain Reaction, RNA Binding Assay, Negative Control, Small Interfering RNA

Effects of LRP11 overexpression on cell viability in SK-OV-3/DDP and A2780/DDP cells with and without KRT14 knockdown. Cells were transfected with si-KRT14 for KRT14 knockdown and LRP11-OP for LRP11 overexpression, while cells transfected with si-NC and EP served as controls. (A,B) LRP11 and KRT14 protein levels, with quantification relative to GAPDH provided below the graphs. (C) Viability of SK-OV-3/DDP and A2780/DDP cells in each group after treatment with various cisplatin concentrations (0, 2.5, 5, 10, 20, 40, and 80 µM). (D) Fitting curves used to determine the IC 50 values for the cells in response to cisplatin. # and & , statistical significance (P<0.05). EP, empty plasmid pcDNA3.1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC 50 , half-maximal inhibitory concentration; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; LRP11-OP, LRP11 overexpression plasmid; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: Effects of LRP11 overexpression on cell viability in SK-OV-3/DDP and A2780/DDP cells with and without KRT14 knockdown. Cells were transfected with si-KRT14 for KRT14 knockdown and LRP11-OP for LRP11 overexpression, while cells transfected with si-NC and EP served as controls. (A,B) LRP11 and KRT14 protein levels, with quantification relative to GAPDH provided below the graphs. (C) Viability of SK-OV-3/DDP and A2780/DDP cells in each group after treatment with various cisplatin concentrations (0, 2.5, 5, 10, 20, 40, and 80 µM). (D) Fitting curves used to determine the IC 50 values for the cells in response to cisplatin. # and & , statistical significance (P<0.05). EP, empty plasmid pcDNA3.1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC 50 , half-maximal inhibitory concentration; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; LRP11-OP, LRP11 overexpression plasmid; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Over Expression, Knockdown, Transfection, Plasmid Preparation, Concentration Assay, Negative Control, Small Interfering RNA

Effects of LRP11 overexpression on apoptosis and MDR-related protein expression in SK-OV-3/DDP and A2780/DDP cells with or without KRT14 knockdown. Cells were transfected with si-KRT14 for KRT14 knockdown and LRP11-OP for LRP11 overexpression, while cells transfected with si-NC and EP served as controls. (A) Apoptotic cell rates assessed using flow cytometry. (B) Apoptotic cell rates assessed using Hoechst 33258 staining. Magnification: 20×. The green arrows indicate the apoptotic cells. (C) P-gp and MRP1 protein levels. Right bar graph: P-gp and MRP1 protein levels relative to GAPDH. # and & , statistical significance (P<0.05). EP, empty plasmid pcDNA3.1; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; LRP11-OP, LRP11 overexpression plasmid; MDR, multidrug resistance; MRP1, multidrug resistance-associated protein 1; P-gp, P-glycoprotein; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Journal: Translational Cancer Research

Article Title: KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines

doi: 10.21037/tcr-24-1795

Figure Lengend Snippet: Effects of LRP11 overexpression on apoptosis and MDR-related protein expression in SK-OV-3/DDP and A2780/DDP cells with or without KRT14 knockdown. Cells were transfected with si-KRT14 for KRT14 knockdown and LRP11-OP for LRP11 overexpression, while cells transfected with si-NC and EP served as controls. (A) Apoptotic cell rates assessed using flow cytometry. (B) Apoptotic cell rates assessed using Hoechst 33258 staining. Magnification: 20×. The green arrows indicate the apoptotic cells. (C) P-gp and MRP1 protein levels. Right bar graph: P-gp and MRP1 protein levels relative to GAPDH. # and & , statistical significance (P<0.05). EP, empty plasmid pcDNA3.1; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; KRT14, keratin 14; LRP11, lipoprotein receptor-related protein 11; LRP11-OP, LRP11 overexpression plasmid; MDR, multidrug resistance; MRP1, multidrug resistance-associated protein 1; P-gp, P-glycoprotein; si-KRT14, siRNA targeting KRT14; si-NC, negative control siRNA; siRNA, small interfering RNA.

Article Snippet: After washing the PVDF membrane with tris-buffered saline with Tween 20 (TBST), it was blocked with 5% non-fat milk at room temperature for 2 h. Subsequently, the membrane was incubated overnight at 4 °C with the primary antibodies against LRP11 (catalogue number: orb674844, Biorbyt, Cambridge, UK), KRT14 (orb1259684, Biorbyt), P-gp (catalogue number: orb11034, Biorbyt), and MRP1 (catalogue number: orb1150958, Biorbyt), following three washes with TBST for 8 min each.

Techniques: Over Expression, Expressing, Knockdown, Transfection, Flow Cytometry, Staining, Plasmid Preparation, Negative Control, Small Interfering RNA